Trial

TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection

Study Director
Start Date
9 / 0
Trial Phase
Trial Status
published
Current Enrollment
8500
Target Enrollment
8000
Overview